Rigel Pharmaceuticals Inc (RIGL) — SEC Filings
Rigel Pharmaceuticals Inc (RIGL) — 40 SEC filings. Latest: 8-K (Dec 10, 2025). Includes 21 8-K, 7 SC 13G/A, 6 10-Q.
View Rigel Pharmaceuticals Inc on SEC EDGAR
Overview
Rigel Pharmaceuticals Inc (RIGL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 10, 2025: On December 7, 2025, Rigel Pharmaceuticals, Inc. filed an 8-K report to disclose other events and financial statements/exhibits. The filing was made on December 10, 2025, and pertains to the company's operations as of December 7, 2025. Rigel Pharmaceuticals is incorporated in Delaware and headquarte
Sentiment Summary
Across 40 filings, the sentiment breakdown is: 2 bullish, 37 neutral, 1 mixed. The dominant filing sentiment for Rigel Pharmaceuticals Inc is neutral.
Filing Type Overview
Rigel Pharmaceuticals Inc (RIGL) has filed 21 8-K, 6 10-Q, 1 DEF 14A, 2 10-K, 7 SC 13G/A, 2 SC 13G, 1 DEFA14A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (40)
Risk Profile
Risk Assessment: Of RIGL's 32 recent filings, 0 were flagged as high-risk, 14 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $69.5M |
| Net Income | $27.9M |
| Cash Position | $48.5M |
| Operating Margin | 40.9% |
| Total Assets | $242.5M |
| Total Debt | $59.7M |
Key Executives
- Dr. V. Michael B. B. Castro
- Dr. David J. Earp
- Ms. Sarah E. Kelly
- December 31, 2023
- February 9, 2024
Industry Context
The pharmaceutical industry is characterized by high R&D costs, long development cycles, and stringent regulatory oversight. Companies like Rigel compete based on innovation, clinical trial success, and effective commercialization strategies. The market for oncology and autoimmune disease treatments, where Rigel focuses, is highly competitive and dynamic.
Top Tags
sec-filing (8) · pharmaceuticals (6) · financial-reporting (5) · amendment (5) · institutional-ownership (5) · financials (4) · SEC Filing (3) · governance (3) · 8-k (3) · operations (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income (Q3 2025) | $27.9M | Increased 124.6% from $12.4M in Q3 2024 |
| Net Income (YTD Sept 2025) | $98.9M | Significantly up from $3.1M in YTD Sept 2024 |
| Product Sales, Net (Q3 2025) | $64.1M | Increased 64.6% from $38.9M in Q3 2024 |
| Product Sales, Net (YTD Sept 2025) | $166.6M | Increased from $98.4M in YTD Sept 2024 |
| Total Revenues (Q3 2025) | $69.5M | Increased 25.6% from $55.3M in Q3 2024 |
| Total Revenues (YTD Sept 2025) | $224.5M | Increased from $121.7M in YTD Sept 2024 |
| Cash and Cash Equivalents (Sept 30, 2025) | $48.5M | Decreased from $56.7M at Dec 31, 2024 |
| Short-term Investments (Sept 30, 2025) | $88.6M | Increased from $20.6M at Dec 31, 2024 |
| Total Stockholders' Equity (Sept 30, 2025) | $117.6M | Increased significantly from $3.3M at Dec 31, 2024 |
| Total Current Liabilities (Sept 30, 2025) | $94.4M | Increased from $63.3M at Dec 31, 2024 |
| Report Period End Date | 2025-06-30 | Latest financial reporting period |
| Filing Date | 2025-08-05 | Date the 10-Q was filed |
| CIK | 0001034842 | Unique identifier for RIGEL PHARMACEUTICALS INC |
| Form Type | 10-Q | Type of SEC filing |
| Film Number | 251184909 | SEC internal tracking number |
Forward-Looking Statements
- {"claim":"Vanguard Group will maintain a significant, but potentially fluctuating, stake in Rigel Pharmaceuticals Inc. throughout 2024.","entity":"The Vanguard Group","targetDate":"December 31, 2024","confidence":"medium"}
- {"claim":"Rigel Pharmaceuticals (RIGL) stock may experience increased investor interest due to Morgan Stanley's significant stake.","entity":"Rigel Pharmaceuticals Inc.","targetDate":"Q1 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Rigel Pharmaceuticals Inc (RIGL)?
Rigel Pharmaceuticals Inc has 40 recent SEC filings from Jan 2024 to Dec 2025, including 21 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RIGL filings?
Across 40 filings, the sentiment breakdown is: 2 bullish, 37 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Rigel Pharmaceuticals Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Rigel Pharmaceuticals Inc (RIGL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Rigel Pharmaceuticals Inc?
Key financial highlights from Rigel Pharmaceuticals Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RIGL?
The investment thesis for RIGL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Rigel Pharmaceuticals Inc?
Key executives identified across Rigel Pharmaceuticals Inc's filings include Dr. V. Michael B. B. Castro, Dr. David J. Earp, Ms. Sarah E. Kelly, December 31, 2023, February 9, 2024.
What are the main risk factors for Rigel Pharmaceuticals Inc stock?
Of RIGL's 32 assessed filings, 0 were flagged high-risk, 14 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Rigel Pharmaceuticals Inc?
Recent forward-looking statements from Rigel Pharmaceuticals Inc include guidance on {"claim":"Vanguard Group will maintain a significant, but potentially fluctuating, stake in Rigel Pharmaceuticals Inc. t and 1 other predictions.